vs

Side-by-side financial comparison of Apyx Medical Corp (APYX) and PEDEVCO CORP (PED). Click either name above to swap in a different company.

PEDEVCO CORP is the larger business by last-quarter revenue ($23.1M vs $19.2M, roughly 1.2× Apyx Medical Corp). Apyx Medical Corp runs the higher net margin — -6.8% vs -36.8%, a 30.1% gap on every dollar of revenue. On growth, PEDEVCO CORP posted the faster year-over-year revenue change (118.2% vs 34.7%). Over the past eight quarters, PEDEVCO CORP's revenue compounded faster (68.6% CAGR vs 36.8%).

Bovie Medical Corporation was an American medical device manufacturer of medical devices, electrosurgical products and energy technologies. It was based in Clearwater, Florida with a manufacturing facility in Bulgaria.

PEDEVCO Corp is an independent energy company specializing in the acquisition, exploration, development, and production of oil and natural gas assets. It primarily holds and operates onshore resource properties across continental US basins, serving domestic wholesale, utility, and industrial energy customer segments.

APYX vs PED — Head-to-Head

Bigger by revenue
PED
PED
1.2× larger
PED
$23.1M
$19.2M
APYX
Growing faster (revenue YoY)
PED
PED
+83.5% gap
PED
118.2%
34.7%
APYX
Higher net margin
APYX
APYX
30.1% more per $
APYX
-6.8%
-36.8%
PED
Faster 2-yr revenue CAGR
PED
PED
Annualised
PED
68.6%
36.8%
APYX

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
APYX
APYX
PED
PED
Revenue
$19.2M
$23.1M
Net Profit
$-1.3M
$-8.5M
Gross Margin
62.6%
Operating Margin
0.1%
-21.3%
Net Margin
-6.8%
-36.8%
Revenue YoY
34.7%
118.2%
Net Profit YoY
71.9%
-243.5%
EPS (diluted)
$-2.23

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
APYX
APYX
PED
PED
Q4 25
$19.2M
$23.1M
Q3 25
$12.9M
$7.0M
Q2 25
$11.4M
$7.0M
Q1 25
$9.4M
$8.7M
Q4 24
$14.2M
$10.6M
Q3 24
$11.5M
$9.1M
Q2 24
$12.1M
$11.8M
Q1 24
$10.2M
$8.1M
Net Profit
APYX
APYX
PED
PED
Q4 25
$-1.3M
$-8.5M
Q3 25
$-2.0M
$-325.0K
Q2 25
$-3.8M
$-1.7M
Q1 25
$-4.2M
$140.0K
Q4 24
$-4.6M
$5.9M
Q3 24
$-4.7M
$2.9M
Q2 24
$-6.6M
$2.7M
Q1 24
$-7.6M
$773.0K
Gross Margin
APYX
APYX
PED
PED
Q4 25
62.6%
Q3 25
64.4%
Q2 25
62.3%
Q1 25
60.1%
Q4 24
63.0%
Q3 24
60.5%
Q2 24
61.7%
Q1 24
58.1%
Operating Margin
APYX
APYX
PED
PED
Q4 25
0.1%
-21.3%
Q3 25
-6.5%
-12.0%
Q2 25
-22.6%
-32.2%
Q1 25
-32.4%
1.7%
Q4 24
-21.4%
-12.9%
Q3 24
-31.6%
31.3%
Q2 24
-45.7%
22.3%
Q1 24
-64.6%
7.6%
Net Margin
APYX
APYX
PED
PED
Q4 25
-6.8%
-36.8%
Q3 25
-15.4%
-4.7%
Q2 25
-33.2%
-24.0%
Q1 25
-44.0%
1.6%
Q4 24
-32.5%
56.0%
Q3 24
-40.9%
32.2%
Q2 24
-54.0%
22.7%
Q1 24
-74.0%
9.5%
EPS (diluted)
APYX
APYX
PED
PED
Q4 25
$-2.23
Q3 25
$0.00
Q2 25
$-0.02
Q1 25
$0.00
Q4 24
$2.69
Q3 24
$0.03
Q2 24
$-0.19
$0.03
Q1 24
$-0.22
$0.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
APYX
APYX
PED
PED
Cash + ST InvestmentsLiquidity on hand
$31.7M
$3.2M
Total DebtLower is stronger
$37.5M
Stockholders' EquityBook value
$14.5M
$207.4M
Total Assets
$66.8M
$375.9M
Debt / EquityLower = less leverage
2.58×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
APYX
APYX
PED
PED
Q4 25
$31.7M
$3.2M
Q3 25
$25.1M
$10.9M
Q2 25
$29.3M
$8.5M
Q1 25
$31.0M
$10.4M
Q4 24
$31.7M
$4.0M
Q3 24
$28.0M
$4.6M
Q2 24
$32.7M
$6.1M
Q1 24
$37.3M
$13.3M
Total Debt
APYX
APYX
PED
PED
Q4 25
$37.5M
Q3 25
$37.5M
Q2 25
$37.5M
Q1 25
$37.5M
Q4 24
$37.5M
Q3 24
$37.5M
Q2 24
Q1 24
Stockholders' Equity
APYX
APYX
PED
PED
Q4 25
$14.5M
$207.4M
Q3 25
$5.8M
$115.4M
Q2 25
$7.3M
$115.2M
Q1 25
$10.5M
$116.2M
Q4 24
$14.2M
$115.6M
Q3 24
$11.0M
$106.5M
Q2 24
$14.7M
$103.2M
Q1 24
$20.3M
$100.0M
Total Assets
APYX
APYX
PED
PED
Q4 25
$66.8M
$375.9M
Q3 25
$57.4M
$135.9M
Q2 25
$58.2M
$136.8M
Q1 25
$60.2M
$145.6M
Q4 24
$64.8M
$128.3M
Q3 24
$60.7M
$114.3M
Q2 24
$65.4M
$111.0M
Q1 24
$70.7M
$118.3M
Debt / Equity
APYX
APYX
PED
PED
Q4 25
2.58×
Q3 25
6.41×
Q2 25
5.17×
Q1 25
3.57×
Q4 24
2.64×
Q3 24
3.40×
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
APYX
APYX
PED
PED
Operating Cash FlowLast quarter
$-2.5M
$-2.1M
Free Cash FlowOCF − Capex
$-2.8M
FCF MarginFCF / Revenue
-14.6%
Capex IntensityCapex / Revenue
1.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-9.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
APYX
APYX
PED
PED
Q4 25
$-2.5M
$-2.1M
Q3 25
$-3.5M
$7.4M
Q2 25
$-1.2M
$-420.0K
Q1 25
$-702.0K
$5.9M
Q4 24
$-2.9M
$4.2M
Q3 24
$-4.4M
$8.3M
Q2 24
$-4.3M
$4.6M
Q1 24
$-6.3M
$-4.3M
Free Cash Flow
APYX
APYX
PED
PED
Q4 25
$-2.8M
Q3 25
$-4.1M
Q2 25
$-1.5M
Q1 25
$-757.0K
Q4 24
$-3.2M
Q3 24
$-4.6M
Q2 24
$-4.6M
Q1 24
$-6.4M
FCF Margin
APYX
APYX
PED
PED
Q4 25
-14.6%
Q3 25
-31.5%
Q2 25
-13.2%
Q1 25
-8.0%
Q4 24
-22.4%
Q3 24
-40.0%
Q2 24
-38.0%
Q1 24
-62.2%
Capex Intensity
APYX
APYX
PED
PED
Q4 25
1.4%
Q3 25
4.0%
Q2 25
2.3%
Q1 25
0.6%
Q4 24
1.7%
Q3 24
1.3%
Q2 24
2.4%
Q1 24
0.3%
Cash Conversion
APYX
APYX
PED
PED
Q4 25
Q3 25
Q2 25
Q1 25
42.34×
Q4 24
0.71×
Q3 24
2.83×
Q2 24
1.71×
Q1 24
-5.56×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons